Sentinel Lymph Node Biopsy in Prostate Cancer: An Overview of Diagnostic Performance, Oncological Outcomes, Safety, and Feasibility-Reference-Cited by-同舟云学术

Sentinel Lymph Node Biopsy in Prostate Cancer: An Overview of Diagnostic Performance, Oncological Outcomes, Safety, and Feasibility

Published:2023-07-31 Issue:15 Volume:13 Page:2543
ISSN:2075-4418
Container-title:Diagnostics
language:en
Short-container-title:Diagnostics

Author:

Rossin Giulio¹,Zorzi Federico¹^ORCID,De Pablos-Rodríguez Pedro²^ORCID,Biasatti Arianna¹,Marenco Josè²,Ongaro Luca¹^ORCID,Perotti Alessandro³,Tulone Gabriele⁴^ORCID,Traunero Fabio¹^ORCID,Piasentin Andrea¹^ORCID,Gomez-Ferrer Alvaro²,Zucchi Alessandro³^ORCID,Trombetta Carlo¹^ORCID,Simonato Alchiede⁴^ORCID,Rubio-Briones José⁵,Bartoletti Riccardo³,Ramírez-Backhaus Miguel²,Claps Francesco¹²^ORCID

Affiliation:

1. Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Strada di Fiume, 447, 34149 Trieste, Italy

2. Department of Urology, Valencian Oncology Institute Foundation, FIVO, 46009 Valencia, Spain

3. Department of Translational Research and New Technologies, University of Pisa, 56126 Pisa, Italy

4. Urology Clinic, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, 90133 Palermo, Italy

5. Clínica de Urología, Hospital VITHAS 9 de Octubre, 46015 Valencia, Spain

Abstract

Sentinel node biopsy (SNB) for prostate cancer (PCa) represents an innovative technique aimed at improving nodal staging accuracy. The routinary adoption of this procedure in patients undergoing radical prostatectomy (RP) might be crucial to identify candidates who could effectively benefit from extensive pelvic lymph nodal dissection (ePLND). Despite some promising results, SNB for PCa is still considered experimental due to the lack of solid evidence and procedural standardization. In this regard, our narrative review aimed to analyze the most recent literature in this field, providing an overview of both the diagnostic accuracy measures and the oncological outcomes of SNB.

Publisher

MDPI AG

Subject

Clinical Biochemistry

Link

https://www.mdpi.com/2075-4418/13/15/2543/pdf

Reference66 articles.

1. Cancer statistics;Siegel;CA Cancer J. Clin.,2022

2. Urologic malignancies: Advances in the analysis and interpretation of clinical findings;Crocetto;Futur. Sci. OA,2021

3. Extended pelvic lymph node dissection in prostate cancer: A 20-year audit in a single center;Abdollah;Ann. Oncol.,2013

4. Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores;Briganti;Eur. Urol.,2011

5. EAU Guidelines (2023). Proceedings of the EAU Annual Congress Milan 2023, Milan, Italy, 10–13 March 2023, EAU Guidelines Office.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing Nodal Staging in Intermediate and High-Risk Prostate Cancer: An Examination of Sentinel Lymph Node Dissection Using ICG/NIR;Lymphatic System - From Human Anatomy to Clinical Practice [Working Title];2023-11-06